Translational Research Institute

The Translational Research Institute (TRI) brings four of the country's pinnacle research facilities together with the aim of improving and accelerating medical research and translating that research into greater palliative care. The TRI will allow biopharmaceuticals and treatments to be discovered, produced, clinically tested and manufactured in one location.

The TRI will focus on a wide range of health and medical research areas including cervical cancer, prostate cancer, breast cancer, melanoma, liver and kidney disease, malaria, HIV, osteoporosis, obesity, arthritis and diabetes.

The TRI is a joint venture between the University of Queensland's Diamantina Institute, Queensland University of Technology's Institute of Health and Biomedical Innovation, Mater Medical Research Institute (MMRI) and the Princess Alexandra Hospital?s Centres for Health Research.

It will house BioPharmaceuticals Australia, the nation's first fully dedicated GMP contract manufacturing facility for mammalian cell-based biotherapeutics.  The facility will be operated by DSM Biologics.

The TRI will combine academic medicine and translational research, in order to minimise the time between a laboratory discovery and its effective application in the clinic and the community.